Abstracts tagged "Adalimumab"

Abstract Number: 497 • 2013 ACR/ARHP Annual Meeting
Development Of a Novel Bispecific Therapeutic For Arthritic Diseases
Mathieu Ferrari¹, Shimobi Onuoha¹, Tahereh Kamalati², Daniele Sblattero³ and Costantino Pitzalis⁴, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry Queen Mary University of London, London, United Kingdom, ²University College of London, London, United Kingdom, ³University of Eastern Piedmont, Novara, Italy, ⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom
Background/Purpose: Despite the obvious success of current biological agents for treatment of rheumatoid arthritis (RA), achievement of broader efficacy and improved safety profile remains an…
Abstract Number: 1467 • 2013 ACR/ARHP Annual Meeting
Adalimumab In Combination With High and Low Dose-Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study
Ghada Ahmed¹, Sandra L Goss¹, Cheri E Klein¹, Neelufar Mozaffarian², Gurjit S. Kaeley³ and Walid Awni¹, ¹AbbVie Inc., North Chicago, IL, ²Eli Lilly, San Diego, CA, ³College of Medicine, University of Florida, Jacksonville, FL
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX) may be initiated on combination therapy with anti-TNF agents such as adalimumab. However, it…
Abstract Number: 499 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial
Robin Christensen¹, Simon Tarp¹, Daniel Furst², Lars E. Kristensen³ and Henning Bliddal⁴, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²David Geffen School of Medicine, University of California, Los Angeles, CA, ³Rheumatology, Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Rheumatology, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Using combined data from the ATTEST [1] and AMPLE [2] study comparing infliximab and adalimumab with abatacept in patients with rheumatoid arthritis (RA), we…
Abstract Number: 1443 • 2013 ACR/ARHP Annual Meeting
Is The Risk Of Tumor Necrosis Factor Inhibitor-Induced Lupus The Same With Monoclonal Antibodies and Soluble Receptor? A Case/Non-Case Study In a Nationwide Pharmacovigilance Database
Guillaume Moulis¹, Agnès Sommet², Maryse Lapeyre-Mestre² and Jean-Louis Montastruc², ¹Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, ²Department of Clinical Pharmacology, Toulouse University Hospital, INSERM U1027, University of Toulouse, France, Toulouse, France
Background/Purpose: Albeit lupus occurring on each TNFi have been reported, no epidemiological study has been conducted to assess the link between lupus onset and each…
Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
Cem Gabay¹, Katie Tuckwell², Jennifer Green², Micki Klearman³ and Arthur Kavanaugh⁴, ¹SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ²Roche, Welwyn Garden City, United Kingdom, ³Roche, South San Francisco, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…
Abstract Number: 157 • 2013 ACR/ARHP Annual Meeting
Application Of a Multiplex Gene Polymorphism Assay For Variants Associated With Rheumatoid Arthritis Susceptibility: Results Of 168 Single Nucleotide Polymorphisms In The Optima Study
Jeffrey F. Waring¹, Viswanath Devanarayan², Kenneth Idler¹, Feng Hong², Josef S. Smolen³, Arthur Kavanaugh⁴, Hartmut Kupper⁵, Hendrik Schulze-Koops⁶ and Alla Skapenko⁷, ¹AbbVie Inc., North Chicago, IL, ²AbbVie Bioresearch Center, Worchester, MA, ³Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴University of California San Diego, La Jolla, CA, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶Division of Rheumatology, University of Munich, Munich, Germany, ⁷Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose: Genetic factors have been identified that may be associated with the development and severity of rheumatoid arthritis (RA), disease progression, or response to treatment.…
Abstract Number: 1423 • 2013 ACR/ARHP Annual Meeting
The Influence Of Body Mass Index On The Efficacy Of Tumor Necrosis Factor Blocking Therapy For Rheumatoid Arthritis
Ingrid M. Visman¹, Inge A.M. van den Oever¹, Charlotte L. M. Krieckaert¹, Gertjan Wolbink¹ and Michael T. Nurmohamed², ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands
Background/Purpose : The impact of Body mass Index (BMI) on efficacy of TNF blocking therapy is an important question, as adipose tissue appears to have…
Abstract Number: 425 • 2013 ACR/ARHP Annual Meeting
Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination With Adalimumab: Results From the Concerto Trial
Gerd Burmester¹, Alan J. Kivitz², Hartmut Kupper³, Udayasankar Arulmani⁴, Stefan Florentinus⁵, Sandra Goss⁴, Suchitrita S. Rathmann⁴ and Roy Fleischmann⁶, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Altoona Center for Clinical Research, Duncansville, PA, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, Rungis, France, ⁶University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Anti-TNF plus methotrexate (MTX) is more effective than either as monotherapy. Thus far, no controlled data are available on the benefit:risk of different doses…
Abstract Number: 2686 • 2013 ACR/ARHP Annual Meeting
Impact of Methotrexate Dose Reduction Upon Initiation of Adalimumab On Clinical and Ultrasonographic Parameters in Patients With Moderate to Severe Rheumatoid Arthritis
Gurjit S. Kaeley¹, Amy M. Evangelisto², Midori Jane Nishio³, Shufang Liu⁴ and Hartmut Kupper⁵, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Arthritis, Rheumatic and Back Disease Associates, Voorhees, NJ, ³Diablo Clinical Research, Walnut Creek, CA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Methotrexate (MTX) is the recommended first-line disease-modifying antirheumatic drug (DMARD) for the treatment of moderately to severely active rheumatoid arthritis (RA). Whether patients (pts)…
Abstract Number: 1409 • 2013 ACR/ARHP Annual Meeting
Long-Term Impact of Delaying Combination Therapy With Adalimumab Plus Methotrexate By 2 Years in Patients With Early Rheumatoid Arthritis: Final 10-Year Results of the Premier Trial
Edward C. Keystone¹, Ferdinand C. Breedveld², Désiréé van der Heijde², Robert Landewe³, Stefan Florentinus⁴, Udayasankar Arulmani⁵, Shufang Liu⁵, Hartmut Kupper⁶ and Arthur Kavanaugh⁷, ¹University of Toronto, Toronto, ON, Canada, ²Leiden University Medical Center, Leiden, Netherlands, ³Academic Medical Center, Amsterdam, Netherlands, ⁴AbbVie, Rungis, France, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁷University of California San Diego, San Diego, CA
Background/Purpose: The PREMIER trial demonstrated the superiority of initial adalimumab (ADA)+MTX vs the individual monotherapies in MTX-naïve patients (pts) with early, aggressive rheumatoid arthritis (RA).…
Abstract Number: 427 • 2013 ACR/ARHP Annual Meeting
US Veterans With Rheumatoid Arthritis Who Switch Among Tumor Necrosis Factor Blocking Agents Have No Additional Clinical Benefit With The Change In Therapy and Incur Higher Costs
Grant W. Cannon¹, Scott L. DuVall², Candace L. Hayden³, Liron Caplan⁴, Jeffrey R. Curtis⁵, Kaleb Michaud⁶, Ted R. Mikuls⁷, Andreas M. Reimold⁸, David H. Collier⁹, George Joseph⁹, David J. Harrison⁹ and Brian C. Sauer¹⁰, ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ³Epidemiology, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁴Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, ⁵Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁹Amgen Inc., Thousand Oaks, CA, ¹⁰Epdemiology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: While tumor necrosis factor (TNF) blockers can be effective in treating rheumatoid arthritis (RA), the benefit of switching among TNF blockers is not clear.…
Abstract Number: 2688 • 2013 ACR/ARHP Annual Meeting
Methotrexate Dose Has Minimal Effects On Methotrexate-Related Toxicity In Patients With Early Rheumatoid Arthritis Treated In Combination With Adalimumab – Results Of Concerto Trial
Gerd Burmester¹, Alan J. Kivitz², Ronald F. van Vollenhoven³, Stefan Florentinus⁴, Piyalal M. Karunaratne⁵, Hartmut Kupper⁶, Maxime Dougados⁷ and Roy Fleischmann⁸, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Altoona Center for Clinical Research, Duncansville, PA, ³The Karolinska Institute, Stockholm, Sweden, ⁴AbbVie, Rungis, France, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁷Hopital Cochin, René Descartes University, Paris, France, ⁸University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Adalimumab is usually used in combination with 15-20 mg methotrexate (MTX) weekly in early rheumatoid arthritis (RA). Lower doses of MTX in combination with…
Abstract Number: 1388 • 2013 ACR/ARHP Annual Meeting
Multiplex Cytokine Analyses In Patients With Rheumatoid Arthritis Require Use Of Agents Blocking Heterophilic Antibody Activity
Peter Olsson¹, Elke Theander², Ulf Bergström³, Stefan Jovinge⁴, Lennart Jacobsson³ and Carl Turesson², ¹Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden
Background/Purpose: Rheumatoid factor (RF) and other circulating heterophilic antibodies have been shown to interfere with antibody-based immunoassays, in particular with multiplex protein detection platforms. Previous…
Abstract Number: 438 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
M. C. Genovese¹, R. F. van Vollenhoven², B. Wilkinson³, L. Wang³, S. H. Zwillich³, D. Gruben³, B. Benda⁴ and T. V. Jones⁴, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, we describe the efficacy and safety for adalimumab (ADA)…
Abstract Number: 2479 • 2013 ACR/ARHP Annual Meeting
Adalimumab Significantly Reduces Inflammation In Active Ankylosing Spondylitis: An Ultrasound Study
Zaiying Hu¹, Manlong Xu², Zetao Liao³, Zhiming Lin⁴ and Jieruo Gu⁵, ¹Rheumatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSIT, Guangzho, China, ³Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ⁴Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ⁵Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: To evaluate the feasibility of using power Doppler ultrasound (PDUS) to detect inflammation in sacroiliac joints and entheses after adalimumab (a TNF-alpha antagonist) treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].